Biosynthetic ε-poly-L-lysine for the treatment of extensively- and pan-drug-resistant Pseudomonas aeruginosa.

ABSTRACT: Pseudomonas aeruginosa (PA) represents a major cause of antimicrobial resistance-related morbidity and mortality. The recent emergence of highly fatal infections, caused by carbapenem-resistant PA, has called for novel antimicrobial therapies and strategies. In this study, we highlight the therapeutic potential of ε-poly-L-lysine (εPL), an antimicrobial polymer for treating extensively-and pan-drug-resistant-PA. εPL displayed potent antimicrobial activity against all eight drug-resistant PA, including carbapenem- and polymyxin-resistant PA. It exhibited a low risk of AMR evolution, with no evidence of cross-resistance with polymyxin B (a last-line treatment for drug-resistant Gram-negative bacteria). We further demonstrated promising in vivo efficacy and safety of εPL against PA in a pre-c

SUBMITTER: Ting DSJ 

PROVIDER: S-EPMC12420815 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature